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Cassileth et al, who explored the relation between
patients' early recognition of superficial spreading
melanoma and depth of invasion,' provide no
support for a direct correlation between time to
excision of the primary lesion and tumour thick-
ness.
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Diuretic treatment in decompensated
cirrhosis and congestive heart failure
SIR,-Dr Helmer Ring-Larsen and others (24
May, p 1351) suggest that the blunted renal
response to a diuretic agent in the upright as
compared with the supine position is due to the
activation of several hormonal mechanisms.
They found evidence for increased activity of the
sympathetic nervous system and of the renin-
aldosterone axis and mention vasopressin as
another important homoeostatic measure. How-
ever, they do not consider the possible role of the
atrial natriuretic factor.
Several observations indicate that this novel
diuretic and natriuretic peptide' has a substantial
role in volume homoeostasis. We and others
have shown that patients with hypertension or
congestive heart failure show greatly increased
plasma concentrations of atrial natriuretic factor,
which are well correlated with right atrial pres-
sures.23 In patients with cirrhosis we showed
that discontinuation of diuretic treatment
could increase circulating concentrations of atrial
natriuretic factor.4 Values in children with renal,
insufficiency are greatly increased and correlate
well with the degree ofvolume expansion; they are
significantly reduced after volume reduction by
haemodialysis.5 Changes in posture influence
plasma atrial natriuretic factor values.6 In the
supine position central venous and right atrial
pressure increase due to volume shifting. Such an
increase, induced by head out water immersion,
has been shown to stimulate release of atrial
natriureticfactorinhealthy subjects7andin patients
with cirrhosis.'
These findings support the contention that atrial
natriuretic factor is an important factor in volume
regulation in health as well as disease. Determina-
tion of atrial natriuretic factor concentrations
might be useful in studies ofvolume regulation and
might elucidate the still unresolved complex of
posture dependent diuresis.
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Non-steroidal anti-inflammatory drugs and
serious gastrointestinal adverse reactions
SIR,-TheCSM update (3 May, p 1190) is a useful
method of approximating the relative risks of non-
steroidal anti-inflammatory drugs and will no
doubt be widely quoted. However, the data for
fenbufen contain an error in that the number of
prescriptions stated has been miscalculated.
Prescription numbers obtained from the DHSS
office of statistics for the time period covered in the
review should have been 1-97 million and not 1-57
million as shown. Fenbufen tablet prescriptions
for 1984 have been inadvertently omitted. Conse-
quently I believe that table II should read (deaths
in parentheses):
Gastrointestinal reactions per milhon prescriptions 28-4(1 5)
Otherserious reactions per milhion prescriptions 26-9(2 0)
Total serious reactions per milhion prescriptions 55*3(3-6)
Although these changes do not radically alter the
general interpretations in this article, I am anxious
for these corrections to be published because this
useful review will no doubt become a much used
reference source.
PHILIP COHEN
Lederle Laboratories,
Gosport,
Hampshire P013 OAS
CSM's REPLY-We acknowledge the error in the
fenbufen data pointed out by Dr Cohen. We wish
to emphasise that prescribers should not use
differences in the reporting rates among drugs in
the second group of table II as a guide to the
relative safety of this' group of drugs. In terms of
overall safety these drugs cannot at present be
clearly distinguished from each other on the basis
of this analysis of yellow card reports.
R D MANN
Committee on Safety of Medicines,
Department ofHealth and Social Security,
London SW8 5NQ
Laboratory equipment
SIR,-I was dismayed by Dr B J Boughton's
flippant and cynical attitude in his Personal View
(24 May, p 1986). Fortunately most pathologists
are more responsible in their efforts to acquire the
tools oftheir trade. At least Dr Boughton can sit on
a committee where resource allocation is' openly
discussed. This was also my experience as a senior
lecturer at King's College Hospital (South East
Thames region), but here the North Western
region makes its decisions by a secret cabal in
Manchester. This system was devised years ago by
canny Mancunians, who perceived the disadvan-
tages in theRAWP principle and have ensured that
the bulk of money for equipment stays in central
Manchester.
The problem here is further compounded by a
disastrous new regional policy to cut the medical
equipmentbudgetby 15%before 1993. DrBough-
ton would doubtless approve of this scheme and
volunteer his own laboratory not to replace its
Couiter counter (bought by a predecessor) when it
becomes too expensive to maintain (although never
worn out, of course). Since he knows that "lab-
oratory tests are almost useless" he could no doubt
use his Neubauer countingchamber for his patients
receiving chemotherapy for leukaemia or lym-
phoma, whose white cells or platelets need to be
counted from time to time.
Virtually all consultants, regardless of specialty,
need sophisticated equipment to enable them to
practise modern medicine. So far the NHS has
quite failed to keep pace with technology because
of its expense. Dr Boughton's plea for nostalgia (to
be polite) may please his hard pressed director of
finance but it won't help his patients very much.
P J N HOWORTH
Departmnt of Pathology,
V-ictoria Hospital,
Blackpool FY3 8NR
Imvrersible pulmonary hypertension after
treatment with fenfluramine
SIR,-We wish to reply to the comments made by
Drs K Watters and A Le Ridant (26 April, p 1137)
regarding our recent case report. '
It is obvious that we were describing the natural
history of a case of plexogenic pulmonary hyper-
tension. We never attempted to suggest otherwise.
In such cases it is essential to look for a specific
cause before resorting to the designation "idio-
pathic." It is therefore not "surprising" that
fenfluramine was considered, given -that three
cases of a possible association with pulmonary
hypertension had already been reported. I Though
a chance association was not inconceivable, the
appearance ofsymptoms, signs, and eectrocardio-
graphic changes ofpulmonary hypertension in two
patients after starting treatment with fenfluramine
and their regression on withdrawal of the drug
seemed significant. This was especially so as these
changes recurred in one patient after rechallenge
with the drug.
As Drs Watters and Le Ridant acknowledge, our
patient's fate was already clear when she presented
with exertional dyspnoea four years before her death.
Their point that she took no fenfluramine during the
last two years of this period is therefore irrelevant,
particularly ifrepeated exposure to this drug can cause
progressive, irreversible pulmonary hypertension. It
was only the possibility of this association that we
wished to raise in our report, and at no point did we
attempt to describe this as an "expected side effect" of
treatment with fenfluramine.
The writers also stated that we "admitted" our
information was "incomplete" and that there was an
"absence of comprehensive medical records." We
totally refute these serious accusations. The informa-
tion on this patient was only "incomplete" in that she
had not required medical attention in hospital in the
period 1977 to 1980 and other detailed information on
drug dosage could not be obtained from her general
practitioner, despite repeated requests. Records con-
cerning her treatment at this hospital in 1976 and
1984-5, and at the referring hospital, are fully
comprehensive.
Drs Watters and Le Ridant admit the need
for conscientious drug surveillance. We agree: if
such a serious adverse reaction as this has been
suggested before it behoves a physician to be
vigilant for it and report it. Ifsuch a side effect does
occur, but only rarely, it will not be commonly
reported; this does not mean it does not exist. In an
obese cigarette smoker, such as our patient, it
would be easy to ascribe breathlessness to another
cause and overlook such an association. The diffi-
culties in establishing cause-effect relations
are clear, but this case meets the criteria for a
"possible" or "conditional" adverse drug reaction
report.45 The Committee on Safety of Medicines
advises that possible serious or unusual reactions to
